68.9 F
New York
Thursday, June 30, 2022

Dyadic International [NASDAQ: DYAI] Inks Licensing Agreement with the Rubic Consortium

Must read

Dyadic International, Inc. [NASDAQ: DYAI] disclosed that it has inked a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium. It has been disclosed by WHO that there are currently fewer than 10 African manufacturers. They have a vaccine production capacity based in 5 countries.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


The strategic vision of Rubic is to establish a vaccine research hub and center for higher learning and R&D facilities. Its vision also includes the foundation of a vaccine manufacturing unit with the infrastructure, processing operations. It also includes capabilities for the manufacture and dissemination of high-quality vaccines throughout the African continent.

Furthermore, as per the agreement, Rubic licensed to use the C1 Platform for the research, development, regulatory support, manufacture, launch, marketing, and commercialization of a COVID-19 vaccine(s) that may be man-made in South Africa and sold in multiple countries on the African continent.

Moreover, it also includes that as per the deal Rubic will be accountable for awarding the projected design and funding of Phase II clinical trial within a particular timeframe of the completed technology transfer and licensing agreement.

More articles

Latest article



Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam